- Annual GAAP revenue of $171.6 million; 42.3% growth over 2009;
pro forma revenue of $182.9 million; 7.1% growth over 2009 and 8.3%
growth on a constant-currency basis
- Adjusted EBITDA of $18.9 million; 32.2% growth over 2009
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a medical device company that designs,
develops, manufactures and markets products for the surgical
treatment of spine disorders, with a focus on treating conditions
related to the aging spine, announced today financial results for
the fourth quarter and full year ended December 31, 2010.
2010 Performance Highlights
- Positioned Alphatec as a global leader within the spine
market.
- Completed acquisition of Scient'x S.A.
- Acquisition created global scale with sales in over 50
countries in all major markets.
- Combined entity is the third-largest global pure-play spinal
implant company.
- Alphatec Spine products launched in all major European markets
and several other major international markets.
- Achieved significant revenue growth in key markets.
- Achieved annual U.S. revenue of $119.9 million, representing
14.7% year-over-year growth on a GAAP basis, and 6.1%
year-over-year growth on a pro forma basis.
- With expanded European product distribution, achieved annual
Europe revenue of $24.2 million, representing more than 490%
year-over-year growth on a GAAP basis, and 16.9% year-over-year
growth on a pro forma basis.
- Achieved annual Asia revenue of $20.0 million, representing
66.8% year-over-year growth on a GAAP basis, and 16.8%
year-over-year growth on a pro forma basis.
- Enhanced product offerings in the Biologics market.
- Launched PureGenTM Osteoprogenitor Cell Allograft in September
2010.
- Established Biologics Division with dedicated sales specialists
and biologics experts to drive biologics product adoption and
provide support for the surgeon community with respect to the
Company's biologics products.
- Enhanced product offerings in the Aging Spine and MIS
markets.
- All proprietary aging spine products, including Osseofix®,
OsseoScrew®, and HelifixTM have been launched in Europe.
- OsseoFix has been used in approximately 1,900 patients and
OsseoScrew has been used in approximately 200 patients in
Europe.
- Illico SE® Percutaneous MIS Screw System, as well as SolusTM
Locking ALIF System, have been launched in Europe.
- MIS revenues for full year 2010 increased more than 480% from
full year 2009.
Dirk Kuyper, the Company's President and Chief Executive
Officer, stated: "I am proud of the performance and results that
our company delivered in 2010. We have successfully positioned
Alphatec Spine as a leader within the spine market, with a broad
and expanded global reach, integrated R&D and manufacturing and
continued focus on both the core spine market as well as
differentiated technologies in Aging Spine, MIS and
Biologics." Mr. Kuyper continued, "As we enter 2011, we remain
confident in our ability to grow faster than the overall spine
market and to drive towards our goal of being the leading global
pure-play spine company. We have the team, the products and the
strategic plan to achieve long-term revenue growth, profitability,
and generation of free cash flow."
Fourth Quarter 2010 Financial Results
Consolidated revenues for the fourth quarter 2010 were $46.0
million, an increase of 38.4% from the $33.3 million reported for
the fourth quarter 2009. U.S. revenues for the fourth quarter
2010 were $32.1 million, an increase of 13.5% from the $28.3
million reported for the fourth quarter 2009. International
revenues (including Europe, Asia and Rest of World) for the fourth
quarter 2010 were $13.9 million, an increase of $8.9 million from
the $5.0 million reported for the fourth quarter 2009.
Gross profit for the fourth quarter 2010 was $31.5 million, an
increase of $9.5 million over fourth quarter 2009 of $22.0 million.
Fourth quarter 2010 gross margin of 68.4% increased over fourth
quarter 2009 gross margin of 66.0%.
Total operating expenses for the fourth quarter 2010 were $33.2
million, an increase of $10.8 million compared to fourth quarter
2009 of $22.4 million. Included in operating expenses for the
fourth quarter 2010 are $6.8 million of expenses that were
generated from the acquired Scient'x subsidiaries. The
additional increase in operating expenses was primarily related to
both sales and marketing expenses and general and administrative
expenses, specifically driven by an increase of legal fees related
to litigation matters.
Net loss for the fourth quarter 2010 was $2.9 million, or
($0.03) per share (basic and diluted), compared with a net loss of
$1.3 million, or ($0.03) per share (basic and diluted) for the
fourth quarter 2009. Contributing to the net loss were costs
associated with the refinancing of our credit facility that
amounted to $1.4 million.
Adjusted EBITDA for the fourth quarter 2010 was $4.4 million
compared to adjusted EBITDA of $5.8 million for the fourth quarter
2009. Adjusted EBITDA represents net income (loss) excluding the
effects of interest, taxes, depreciation, amortization, stock-based
compensation costs, and other non-recurring income or expense
items, such as in-process research and development expense and
transaction-related expenses.
Full Year 2010 Financial Results
Consolidated revenues for full year 2010 were $171.6 million, an
increase of 42.3% from the $120.6 million reported for full year
2009. U.S. revenues for full year 2010 were $119.9 million, an
increase of 14.7% from the $104.5 million reported for full year
2009. International revenues (including Europe, Asia and Rest
of World) for full year 2010 were $51.7 million, an increase of
$35.6 million from the $16.1 million reported for full year
2009.
Pro forma revenues for full year 2010 were $182.9 million, an
increase of 7.1% from the $170.8 million for full year 2009.
Gross profit for full year 2010 was $112.8 million, an increase
of $31.8 million over full year 2009 of $81.0 million. Full year
2010 gross margin was 65.7%, a decrease of 1.5% from full year 2009
gross margin of 67.2%.
Total operating expenses for full year 2010 were $124.6 million,
an increase of $33.4 million over full year 2009 of $91.2 million.
Included in operating expenses for full year 2010 are $17.3 million
of expenses that were generated from the acquired Scient'x
subsidiaries, as well as $6.1 million in transaction and
restructuring-related expenses. The additional increase in
operating expenses was primarily related to both sales and
marketing expenses and general and administrative expenses.
Net loss for full year 2010 was $14.4 million, or ($0.18) per
share (basic and diluted), compared with a net loss of $13.3
million, or ($0.27) per share (basic and diluted) for full year
2009.
Adjusted EBITDA for full year 2010 was $18.9 million compared to
adjusted EBITDA of $14.3 million for full year 2009.
2011 Financial Guidance
The Company anticipates annual 2011 revenues of $195.0 million
to $205.0 million, and $25.0 million to $28.0 million in annual
adjusted EBITDA. The Company anticipates generating
both net income and positive free cash flow in 2011.
Conference Call
Alphatec Spine will host a conference call today at 2:00 p.m. PT
/ 5:00 p.m. ET to discuss the results. To participate in the
conference call, please visit the investor relations section of the
Alphatec Spine website at www.alphatecspine.com. The dial-in
numbers are (877) 556-5251 for domestic callers and (720) 545-0036
for international. A live webcast of the conference call will be
available online from the investor relations section of the
Alphatec Spine website at www.alphatecspine.com. The webcast will
be recorded and will remain available on the investor relations
section of Alphatec Spine's website for at least 30 days.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device
company that designs, develops, manufactures and markets products
for the surgical treatment of spine disorders, primarily focused on
the aging spine. The Company's mission is to combine
world-class customer service with innovative, surgeon-driven design
that will help improve the aging patient's quality of
life. The Company is poised to achieve its goal through new
solutions for patients with osteoporosis, stenosis and other aging
spine deformities, improved minimally invasive products and
techniques and integrated biologics solutions. In addition to
its U.S. operations, the Company also markets its products in over
50 international markets through its subsidiary, Scient'x S.A.S.,
via a direct sales force in France, Italy and the United Kingdom
and via independent distributors in the rest of Europe, the Middle
East and Africa, South America and Latin America. In Asia and
Australia, the Company markets its products through its subsidiary,
Alphatec Pacific, Inc, and through Scient'x's distributors in
China, Korea and Australia.
The Alphatec Holdings, Inc. logo is available
athttp://www.globenewswire.com/newsroom/prs/?pkgid=3520
Non-GAAP Information
Non-GAAP earnings included in this press release is a non-GAAP
(generally accepted accounting principles) financial measure that
represents net income (loss) excluding the effects of in-process
research and development expenses, transaction-related expenses and
litigation settlement expenses. Management does not consider these
expenses when it makes certain evaluation of the operations of the
Company. Non-GAAP earnings, as defined above, may not be similar to
non-GAAP earnings measures used by other companies and is not a
measurement under GAAP.
Adjusted EBITDA included in this press release is a non-GAAP
financial measure that represents net income (loss) excluding the
effects of interest, taxes, depreciation, amortization, stock-based
compensation costs, and other non-recurring income or expense
items, such as in-process research and development expense and
transaction-related expenses. Adjusted EBITDA, as defined above,
may not be similar to adjusted EBITDA measures used by other
companies and is not a measurement under GAAP.
Though management finds non-GAAP-based earnings or loss and
EBITDA useful for evaluating aspects of the Company's business, its
reliance on these measures are limited because excluded items often
have a material effect on the Company's earnings and earnings per
common share calculated in accordance with GAAP. Therefore,
management uses non-GAAP adjusted EBITDA in conjunction with GAAP
earnings and earnings per common share measures. The Company
believes that non-GAAP adjusted EBITDA provides investors with an
additional tool for evaluating the Company's core performance,
which management uses in its own evaluation of continuing operating
performance, and a base-line for assessing the future earnings
potential of the Company. While the GAAP results are more complete,
the Company prefers to allow investors to have supplemental metrics
since, with reconciliation to GAAP, they may provide greater
insight into the Company's financial results.
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no
assurance that actual results or business conditions will not
differ materially from those projected or suggested in such
forward-looking statements as a result of various factors,
including, but not limited to, the following: Alphatec Spine's
ability to meet its 2011 revenue, adjusted EBITDA, free cash flow
and earnings projections, the ability to successfully integrate
Scient'x and Alphatec, the growth rate of the spine market related
to aging and elderly patients, uncertainty of success in developing
new products or products currently in Alphatec Spine's pipeline,
the successful global launch of the Company's new products and the
products in its development pipeline including OsseoFix,
OsseoScrew, HeliFix, Solus, PureGen and Illico SE, failure to
achieve acceptance of Alphatec Spine's products by the surgeon
community, failure to obtain FDA clearance or approval for new
products, or unexpected or prolonged delays in the process,
Alphatec Spine's ability to develop and expand its U.S. and/or
global revenues, continuation of favorable third party payor
reimbursement for procedures performed using Alphatec Spine's
products, unanticipated expenses or liabilities or other adverse
events affecting cash flow or Alphatec Spine's ability to
successfully control its costs or achieve profitability,
uncertainty of additional funding, Alphatec Spine's ability to
compete with other competing products and with emerging new
technologies, product liability exposure, patent infringement
claims and claims related to Alphatec Spine's intellectual
property. Please refer to the risks detailed from time to time in
Alphatec Spine's SEC reports, including quarterly reports on Form
10-Q, reports on Form 8-K and annual reports on Form 10-K. Alphatec
Spine disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
| ALPHATEC HOLDINGS,
INC. |
| CONDENSED CONSOLIDATED
BALANCE SHEETS |
| (in thousands -
unaudited) |
| |
|
|
| |
|
|
| |
December 31, |
December 31, |
| |
2010 |
2009 |
| ASSETS |
|
|
| Current assets: |
|
|
| Cash and cash
equivalents |
$ 23,168 |
$ 10,085 |
| Accounts receivable,
net |
39,777 |
24,766 |
| Inventories,
net |
51,635 |
29,515 |
| Prepaid expenses and
other current assets |
6,652 |
3,128 |
| Deferred income tax
assets |
1,592 |
128 |
| Total current assets |
122,824 |
67,622 |
| |
|
|
| Property and equipment, net |
38,440 |
30,356 |
| Goodwill |
170,194 |
60,113 |
| Intangibles, net |
43,148 |
2,296 |
| Other assets |
2,410 |
1,501 |
| Total assets |
$ 377,016 |
$ 161,888 |
| |
|
|
| LIABILITIES AND STOCKHOLDERS'
EQUITY |
|
|
| Current liabilities: |
|
|
| Accounts
payable |
$ 15,957 |
$ 12,781 |
| Accrued
expenses |
22,530 |
16,439 |
| Deferred
revenue |
3,396 |
2,135 |
| Current portion of
long-term debt |
1,708 |
6,724 |
| Total current liabilities |
43,591 |
38,079 |
| |
|
|
| Total long term
liabilities |
43,388 |
25,377 |
| Redeemable preferred
stock |
23,603 |
23,603 |
| Stockholders'
equity |
266,434 |
74,829 |
| Total liabilities and stockholders'
equity |
$ 377,016 |
$ 161,888 |
| |
| ALPHATEC HOLDINGS,
INC. |
| CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS |
| (in thousands,
except per share amounts - unaudited) |
| |
|
|
|
|
| |
|
|
|
|
| |
Three Months Ended |
Year Ended |
| |
December 31, |
December 31, |
| |
2010 |
2009 |
2010 |
2009 |
| |
|
|
|
|
| Revenues |
$ 46,018 |
$ 33,260 |
$ 171,610 |
$ 120,618 |
| Cost of revenues |
14,141 |
11,295 |
57,657 |
39,606 |
| Amortization of acquired intangible
assets |
394 |
-- |
1,136 |
-- |
| Total cost of
revenues |
14,535 |
11,295 |
58,793 |
39,606 |
| Gross profit |
31,483 |
21,965 |
112,817 |
81,012 |
| |
|
|
|
|
| Operating expenses: |
|
|
|
|
| Research and
development |
4,084 |
3,554 |
16,431 |
13,487 |
| In-process research and
development |
-- |
550 |
2,967 |
6,383 |
| Sales and marketing |
18,971 |
12,778 |
66,542 |
49,396 |
| General and
administrative |
9,578 |
4,117 |
31,078 |
19,333 |
| Amortization of acquired
intangible assets |
533 |
-- |
1,535 |
-- |
| Transaction related
expenses |
20 |
1,358 |
3,671 |
2,598 |
| Restructuring
expenses |
(7) |
-- |
2,382 |
-- |
| Total operating
expenses |
33,179 |
22,357 |
124,606 |
91,197 |
| Operating loss |
(1,696) |
(392) |
(11,789) |
(10,185) |
| Interest and other income
(expense), net |
(2,335) |
(685) |
(4,698) |
(3,193) |
| Loss from continuing operations before
taxes |
(4,031) |
(1,077) |
(16,487) |
(13,378) |
| Income tax benefit |
(1,155) |
(70) |
(2,054) |
(138) |
| Loss from continuing
operations |
(2,876) |
(1,007) |
(14,433) |
(13,240) |
| Income (loss) from
discontinued operations, net of tax |
-- |
(313) |
78 |
(49) |
| |
|
|
|
|
| Net loss |
$ (2,876) |
$ (1,320) |
$ (14,355) |
$ (13,289) |
| |
|
|
|
|
| |
|
|
|
|
| Net loss per common share: |
|
|
|
|
| Basic and diluted net
loss from continuing operations |
$ (0.03) |
$ (0.02) |
$ (0.18) |
$ (0.27) |
| Basic and diluted net
income (loss) from discontinued operations |
-- |
(0.01) |
0.00 |
(0.00) |
| Basic and diluted net
loss per share |
$ (0.03) |
$ (0.03) |
$ (0.18) |
$ (0.27) |
| |
|
|
|
|
| Weighted-average shares - basic and
diluted |
88,078 |
51,908 |
78,590 |
49,292 |
| |
| ALPHATEC HOLDINGS,
INC. |
| RECONCILIATION OF
NON-GAAP FINANCIAL MEASURES |
| (in thousands, except
per share amounts - unaudited) |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Three Months Ended |
Year Ended |
| |
December 31, |
December 31, |
| |
2010 |
2009 |
2010 |
2009 |
| |
|
|
|
|
| Operating loss, as reported |
$ (1,696) |
$ (392) |
$ (11,789) |
$ (10,185) |
| Add back: |
|
|
|
|
| Depreciation |
3,664 |
2,393 |
13,126 |
8,627 |
| Amortization of intangible assets |
204 |
919 |
1,449 |
3,329 |
| Amortization of acquired intangible
assets |
927 |
-- |
2,671 |
-- |
| Total EBITDA |
3,099 |
2,920 |
5,457 |
1,771 |
| |
|
|
|
|
| Add back significant items: |
|
|
|
|
| Stock-based compensation |
851 |
1,008 |
3,177 |
3,571 |
| In-process research and
development |
-- |
550 |
2,967 |
6,383 |
| Acquisition-related inventory
step-up |
449 |
-- |
1,281 |
-- |
| Transaction related expenses |
20 |
1,358 |
3,671 |
2,598 |
| Restructuring expenses |
(7) |
-- |
2,382 |
-- |
| |
|
|
|
|
| EBITDA, as adjusted for significant
items |
$ 4,412 |
$ 5,836 |
$ 18,935 |
$ 14,323 |
| |
|
|
|
|
| |
|
|
|
|
| Net loss, as reported |
$ (2,876) |
$ (1,320) |
$ (14,355) |
$ (13,289) |
| Add back: |
|
|
|
|
| In-process research and
development |
-- |
550 |
2,967 |
6,383 |
| Acquisition-related inventory
step-up |
449 |
-- |
1,281 |
-- |
| Amortization of acquired intangible
assets |
927 |
-- |
2,671 |
-- |
| Transaction related expenses |
20 |
1,358 |
3,671 |
2,598 |
| Restructuring expenses |
(7) |
-- |
2,382 |
-- |
| |
|
|
|
|
| Net income (loss), as adjusted for
significant items |
$ (1,487) |
$ 588 |
$ (1,383) |
$ (4,308) |
| |
|
|
|
|
| |
|
|
|
|
| Net loss per common share - basic and
diluted |
$ (0.03) |
$ (0.03) |
$ (0.18) |
$ (0.27) |
| Add back: |
|
|
|
|
| In-process research and
development |
-- |
0.01 |
0.04 |
0.13 |
| Acquisition-related inventory
step-up |
0.00 |
-- |
0.01 |
-- |
| Amortization of acquired intangible
assets |
0.01 |
-- |
0.03 |
-- |
| Transaction related expenses |
0.00 |
0.03 |
0.05 |
0.05 |
| Restructuring expenses |
(0.00) |
-- |
0.03 |
-- |
| |
|
|
|
|
| Net loss per common share - basic and
diluted, as adjusted for significant items |
$ (0.02) |
$ 0.01 |
$ (0.02) |
$ (0.09) |
| |
| ALPHATEC HOLDINGS,
INC. |
| RECONCILIATION OF
GEOGRAPHIC SEGMENT REVENUES AND GROSS PROFIT |
| (in thousands, except
percentages - unaudited) |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Three Months Ended |
|
Impact from |
| |
December 31, |
|
Foreign |
| |
2010 |
2009 |
% Change |
Currency |
| |
|
|
|
|
| Revenues by geographic segment |
|
|
|
|
| U.S. |
$ 32,117 |
$ 28,288 |
13.5% |
0.0% |
| Europe |
5,699 |
1,686 |
238.0% |
-7.2% |
| Asia |
5,733 |
3,286 |
74.5% |
-1.6% |
| Rest of world |
2,469 |
-- |
100.0% |
-7.2% |
| Total revenues |
$ 46,018 |
$ 33,260 |
38.4% |
-1.6% |
| |
|
|
|
|
| Gross profit by geographic segment |
|
|
|
|
| U.S. |
$ 25,082 |
$ 19,301 |
|
|
| Europe |
2,337 |
777 |
|
|
| Asia |
3,267 |
1,887 |
|
|
| Rest of world |
797 |
-- |
|
|
| Total gross profit |
$ 31,483 |
$ 21,965 |
|
|
| |
|
|
|
|
| Gross profit margin by geographic
segment |
|
|
|
|
| U.S. |
78.1% |
68.2% |
|
|
| Europe |
41.0% |
46.1% |
|
|
| Asia |
57.0% |
57.4% |
|
|
| Rest of world |
32.3% |
0.0% |
|
|
| Total gross profit margin |
68.4% |
66.0% |
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Year Ended |
|
Impact from |
| |
December 31, |
|
Foreign |
| |
2010 |
2009 |
% Change |
Currency |
| |
|
|
|
|
| Revenues by geographic segment |
|
|
|
|
| U.S. |
$ 119,880 |
$ 104,531 |
14.7% |
0.0% |
| Europe |
24,242 |
4,101 |
491.1% |
-7.3% |
| Asia |
19,998 |
11,986 |
66.8% |
2.6% |
| Rest of world |
7,490 |
-- |
100.0% |
-7.3% |
| Total revenues |
$ 171,610 |
$ 120,618 |
42.3% |
-1.2% |
| |
|
|
|
|
| Gross profit by geographic segment |
|
|
|
|
| U.S. |
$ 89,226 |
$ 72,401 |
|
|
| Europe |
9,616 |
1,742 |
|
|
| Asia |
11,173 |
6,869 |
|
|
| Rest of world |
2,802 |
-- |
|
|
| Total gross profit |
$ 112,817 |
$ 81,012 |
|
|
| |
|
|
|
|
| Gross profit margin by geographic
segment |
|
|
|
|
| U.S. |
74.4% |
69.3% |
|
|
| Europe |
39.7% |
42.5% |
|
|
| Asia |
55.9% |
57.3% |
|
|
| Rest of world |
37.4% |
0.0% |
|
|
| Total gross profit margin |
65.7% |
67.2% |
|
|
| |
|
|
|
|
| |
|
|
|
|
| Footnotes: |
|
|
|
|
| 1) IMC operating results
have been removed from Asia revenues and gross profit for the
periods presented. |
| |
|
|
|
|
| 2) The impact from foreign
currency represents the percentage change in 2010 revenues due to
the change in foreign |
| exchange rates for the periods
presented. |
|
|
|
|
| |
| ALPHATEC HOLDINGS,
INC. |
| PRO FORMA REVENUES BY
GEOGRAPHIC SEGMENT |
| (in thousands, except
percentages - unaudited) |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Three Months Ended |
% Change |
| |
December 31, |
|
Constant |
| |
2010 |
2009 |
Reported |
Currency |
| |
|
|
|
|
| Pro Forma Revenues by geographic segment |
|
|
|
|
| U.S. |
$ 32,117 |
$ 31,219 |
2.9% |
2.9% |
| Europe |
5,699 |
7,366 |
-22.6% |
-16.6% |
| Asia |
5,733 |
4,878 |
17.5% |
19.4% |
| Rest of world |
2,469 |
3,167 |
-22.0% |
-16.0% |
| Total revenues |
$ 46,018 |
$ 46,630 |
-1.3% |
0.2% |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Year Ended |
% Change |
| |
December 31, |
|
Constant |
| |
2010 |
2009 |
Reported |
Currency |
| |
|
|
|
|
| Pro Forma Revenues by geographic segment |
|
|
|
|
| U.S. |
$ 122,855 |
$ 115,826 |
6.1% |
6.1% |
| Europe |
29,097 |
24,887 |
16.9% |
24.6% |
| Asia |
21,657 |
18,548 |
16.8% |
14.0% |
| Rest of world |
9,336 |
11,582 |
-19.4% |
-14.3% |
| Total revenues |
$ 182,945 |
$ 170,843 |
7.1% |
8.3% |
| |
|
|
|
|
| |
|
|
|
|
| Footnotes: |
|
|
|
|
| 1) IMC operating results
have been removed from Asia pro forma revenues for the periods
presented. |
|
| |
|
|
|
|
| 2) Pro Forma revenues for
the perods presented include the results of Scient'x as if the
Scient'x acquisition had occurred on |
| January 1, 2009. |
|
|
|
|
| |
|
|
|
|
| 3) % Change - Constant
Currency represents the change in 2010 pro forma revenue had the
2010 foreign exchange |
| rates remained constant with 2009
foreign exchange rates. |
|
|
|
CONTACT: Michael O'Neill
Chief Financial Officer
Alphatec Spine, Inc.
(760) 494-6746
investorrelations@alphatecspine.com
Westwicke Partners
Lynn C. Pieper
(415) 202-5678
lynn.pieper@westwicke.com
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
